Loading…
Anti Cancer Drugs GENERIC
Chittaranjan National Cancer Institute · 24 Paraganas North, West Bengal2026_CNCI_917084_1
Written by TenderKart AI from the documents published when it was generated. Check the tender for later corrigenda before you bid.
13 Jul 2026
13 Aug 2026
₹2 L
All important dates as they stand after corrigenda: publication, pre-bid/clarification deadline, bid submission deadline, bid opening, and bid validity period.
The tender PDF does not print the publication, bid-submission or bid-opening timestamps; it directs bidders to the CPPP Critical Date Sheet. Queries must be raised at least 7 days before tender closing; the pre-bid meeting is stated to be already done.
180 days after opening of the Technical Bid; a shorter validity is rejected.
Tender value or estimated cost, EMD/bid security (amount, acceptable forms, validity), tender document fees, performance security, and key payment terms.
Rs. 2,00,000.00 (Rupees Two Lakh only), payable to “Director, CNCI” at Kolkata. The instrument must remain valid 45 days beyond final bid validity. Page 4 internally conflicts on acceptable forms: clause (a) says only DD, while clause (b) also lists account-payee DD, FDR, banker’s cheque or bank guarantee from nationalized banks; bid conservatively with DD and seek confirmation.
Successful bidder(s) must furnish a Performance Bank Guarantee of ₹5,00,000 for each participating institute within 30 working days from signing the Rate Contract; a purchasing institute may impose a more stringent amount or validity under its own policy.
No estimated tender value is stated and the BOQ uses nominal quantity 1 and zero estimated rates. Quote only in INR; rates are to include supplies, customs duty and other taxes, remain fixed during the Rate Contract except approved statutory levy changes, and must not exceed MRP. For DPCO/NLEM drugs, payment is the controlled price or offered rate, whichever is lower.
Submit bills to CNCI Accounts/designee within 15 working days of supply. Correct bills are payable within 45 working days after delivery; corrected invoices restart that 45-working-day period. The supplier cannot stop deliveries for payment delay.
Every pass/fail eligibility and qualification requirement: experience and past performance, turnover/net worth, registrations and certifications, consortium/JV rules, and debarment or blacklisting conditions.
Direct drug manufacturers or marketing companies may bid. A distributor may participate only where the foreign manufacturer has no direct India office, or under the stated India-office/import-license exception with manufacturer authorization and Annexure V affidavit. The participating company may name a maximum of one authorized vendor. No consortium/JV route is stated.
Bidder must have annual turnover of at least Rs 100 Cr for each of the last three financial years for supply of medicines, supported by CA-certified audited balance sheet, profit and loss statement, schedules and notes for 2022-23, 2023-24 and 2024-25. A separate CA-certified oncology turnover statement for the last three years is also required; no net-worth threshold is stated.
Each quoted item must ordinarily have at least 3 years’ market standing after DCGI approval, and the manufacturer must prove at least five commercial batches per year in the last 3 consecutive years. Exception: generic/biosimilar products launched after patent expiry up to bid closing, subject to DCGI approval letter and Director CNCI’s decision. Bidder must also show government oncology-drug supply experience in the last 5 years and three-year institutional performance/supply evidence.
For each product/facility, submit valid manufacturing/marketing authorization/FDA/import licence, State FDA licence and applicable WHO-GMP/cGMP or USFDA/EMEA/Western Europe/Canada/France/Japan/Australia approval. Where an approval certificate has no stated validity, its issue date must be no more than one year before bid submission. Technical checklist also requests applicable IPF/USFDA/CE/ISO/DGQA certificates, past 3-year FDA/CDSCO performance certificate, and third-party analytical reports.
Submit applicable Factories Act/Shops & Establishments/SSI/MSME registration, GST registration, PAN, last two years’ income-tax assessment certificates and a valid FDA/CDSCO no-conviction certificate. Bidders from a country sharing a land border with India must be registered with the DPIIT Registration Committee.
Bidder must declare on Rs.100 non-judicial stamp paper, notarized, that neither it nor relevant owners/directors have been debarred, blacklisted, penalized or convicted as detailed in Annexure VI during the last 5 years, and disclose pending court cases. A separate list of litigations involving institutions/hospitals/organizations during the last 5 years is mandatory. CNCI may reject violations and may debar future participation for tender/rate-contract default.
Firms with a common proprietor/partner, specified financial/principal-agent/master-servant connection, or close family relationship cannot bid separately for the same contract; all such bids are rejected and deposits forfeited. Any missing/evasive required information may reject the bid. For a single-bid situation, supply details and government PO/rate-contract copies may be required.
What is being procured: the work, supplies or services, deliverables and quantities, locations, phases, completion or delivery timelines, applicable standards, and notable exclusions.
Supply generic anti-cancer/chemotherapy medicinal items under a two-year rate contract for both CNCI campuses. Annexure I lists 59 drug/strength lines, from INJ 5 FLUROURACIL 500 MG through TAB Venetoclax 100 MG. Actual demand is variable and no minimum purchase quantity is guaranteed.
Free delivery at site to CNCI, with transit costs borne by the supplier. Each PO states exact quantities and due date. Normal delivery should not exceed 30 ± 2 days; it may be reduced by 15 ± 2 days and further reduced for emergencies after prior intimation.
Products must state IP/BP/USP/EU pharmacopoeial specification and comply with the Drugs and Cosmetics Act, 1940. Supply in one lot/batch with minimum 75% shelf life; imported medicines may be accepted at 50% shelf life only with replacement declaration. Cold-chain products require maintained 2–8°C logistics, monitoring evidence and proof with each supply.
Quote the specified minimum selling-unit pack. Loose, damaged or tampered packs are rejected. Standard boxes must carry “FOR SALE IN CNCI ONLY”, valid individual QR/bar code and batch report (emergency exception only when CNCI asks). Supplier must replace deteriorated, near-expiry, expired, non-moving or unused stock at no cost, or issue credit note where allowed.
The complete checklist of documents to submit — mandatory vs conditional, with any prescribed formats, proformas or annexures — plus how to submit: portal and mode, envelope/cover structure, digital signature requirements, signing and attestation rules, and physical originals with their deadline.
Submit online at the CPPP/eProcure portal using a Class II or III DSC. The nominal two-bid system is implemented as four online covers: Fee; Pre-Qualification; Technical Evaluation; Financial/Price. The complete process is online.
Checklist PDFs and supporting scans must be signed and stamped by the authorized signatory. Upload Checklist I and its documents as one signed/sealed PDF, Checklist II plus signed technical sheet as one signed/sealed PDF, the editable technical sheet separately as XLS/XLSX, and the unmodified BOQ as XLS. Do not place any price information outside the BOQ.
No fixed physical-original submission deadline is stated. CNCI may later demand duly signed hard copies for verification; if uploaded and hard copies differ, the uploaded document prevails. The EMD clauses call for an instrument along with the bid while the cover table asks for an EMD receipt scan, so confirm the original-instrument delivery procedure before bidding.
Every corrigendum/addendum in order — what changed (original vs amended value), its impact, and the action for the bidder — ending with the values that finally apply.
The AI found nothing to report for this question.
Genuine conflicts within and across the documents (original vs corrigenda, clause vs annexure, tender document vs BOQ): both sides with citations, and which value prevails.
Section II(iii)(a) says only DD is accepted, while the immediately following clause permits DD, FDR, banker’s cheque or bank guarantee from nationalized banks. No corrigendum resolves this; use DD unless CNCI confirms otherwise.
Page 4 exempts specified same-item registered bidders, but page 13 says EMD must be submitted or participation is cancelled. The specific exemption should logically apply, but the absolute later wording creates rejection risk; obtain written portal clarification.
The NIT medicine list ends at item 59, but the mandatory BOQ adds items 60–68 as “medicine 1” to “medicine 9”. Extracted BOQ rows also carry unrelated hidden/trailing construction descriptions such as sluice-plate chambers. Because the live BOQ must not be modified, CNCI must issue a corrected BOQ or explicit pricing instruction; neither source can safely prevail for submission.
Annexures III, VI and VII still show 2023 dating, and Annexure VII accepts a “rate contract 2023-25”, whereas this tender is CNCI/e NIT-119/2026-27. The current tender number and current execution date should prevail, but bidders cannot change prescribed language without confirmation because the checklist prohibits format/language changes.
The main contact clause prints [email protected], while Annexure IV directs drug-form queries to [email protected]. Use the CPP Portal for formal clarification and copy both addresses if email is used.
Only critical, tender-specific pre-bid queries that could materially change bid/no-bid, pricing, eligibility or contractual risk. Skip generic or obvious questions the documents already answer clearly.
Ask CNCI to replace/clarify BOQ_963762.xls: should bidders quote only NIT Annexure I items 1–59, or also placeholder items 60–68? Also request removal of unrelated construction text embedded in the workbook. This directly affects price-bid validity and cannot be self-corrected because template modification is prohibited.
Ask whether only DD is accepted or whether FDR/banker’s cheque/BG is valid; whether CPO/DGS&D/NSIC/MoD exemption survives the absolute page-13 mandate; and where/by when the original instrument must arrive, since the online cover asks only for a receipt scan.
Request clean 2026-27 versions of Annexures III, VI and VII, or written permission to replace the stale year/“rate contract 2023-25” text with the current tender reference and date despite the no-format-change rule.
Ask for the exact SLA that will apply per category/campus and the complete CNCI policy referenced by the tender. The text states 30 ± 2 days, possible reduction by 15 ± 2 days, further emergency reduction, and repeated “or as per CNCI policy” overrides that materially affect stockholding and penalties.
Confirm whether Mumbai jurisdiction is an error and should instead be Kolkata/West Bengal, because CNCI and both delivery campuses are in Kolkata while clauses 26–27 assign exclusive Mumbai jurisdiction.
Commercial, legal and execution risks a bidder should weigh: liquidated damages and penalties, unusual or one-sided clauses, tight timelines, and payment or security risks.
Late supply attracts LD of 0.5% per week or part, capped at 10% of PO value, recoverable from security/pending bills. CNCI may buy in the market and recover price difference plus 5% plus GST administrative cost, forfeit EMD, suspend the firm, terminate and record adverse past performance.
Normal SLA is 30 ± 2 days, can be reduced by 15 ± 2 days and further in emergencies. Three failures to supply ordered molecules can summarily discontinue the rate contract; a failed L1 order moves to L2 for the remaining term. Orders placed on or just before contract expiry must still be honored.
CNCI guarantees no minimum quantity and demand varies. Supplier must replace deteriorated, near-expiry, expired, non-moving and unused stock at no cost or issue credit, while imported product may be accepted with only 50% shelf life subject to replacement declaration. This transfers demand and expiry risk to the vendor.
Rates remain fixed with no foreign-exchange revision; MRP reductions must flow through pro rata, DPCO/NLEM pays the lower controlled/offered rate, and Annexure VII imposes a fall-clause declaration. Late delivery also loses later statutory tax increases while CNCI retains later tax decreases.
Payment is targeted 45 working days after a correct bill, but CNCI policy may govern and invoice discrepancies restart the clock. Supplier cannot suspend deliveries for delayed payment. PBG is ₹5 lakh per participating institute, with possible stricter institute-specific amount/validity.
CNCI may terminate the entire/partial rate contract at discretion on 30 days’ notice, or without notice for listed defaults; insolvency termination carries no compensation. Arbitration is by a sole appointee of Director CNCI, potentially a CNCI employee, and the document assigns exclusive Mumbai jurisdiction despite Kolkata performance.
The mandatory BOQ appears contaminated by placeholder medicine rows and unrelated construction text, yet modification is prohibited and any hidden/tampered price information triggers rejection. Pricing without a corrected workbook creates a material responsiveness and evaluation risk.
The inviting authority and relevant contacts: office, person, designation, address, phone and email — and which address receives physical submissions, if any.
The Director, Chittaranjan National Cancer Institute. Formal bids/queries are addressed to the Director at CNCI, Street No.299, Plot No. DJ–01, Premises No. 02-0321, Action Area ID, New Town, Kolkata – 700160. Main contact email printed is [email protected]; no phone number or named contact person is provided.
The tender covers the New Town campus above and the 1st Campus at 37, S.P. Mukherjee Road, Kolkata–700026. Annexure IV separately prints [email protected] for queries; formal clarifications are to be raised through the CPP Portal.